KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 31.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was 0.00 shares.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 807.00 shares, a 89.91% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-06-30 was -7.71K shares, a 181.78% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.77K shares, a 54.87% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 3.93K shares, a 42.47% decline from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 6.83K shares, a 507.65% increase from fiscal 2021.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 1.12K shares, a 66.28% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 31.09K shares 10-Q · filed 2026-08-07 | ||||
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-09 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-25 | 807.00 shares derived: sum of 3 quarters · filed 2026-03-25 | -6.90K shares derived: sum of 4 quarters · filed 2026-03-25 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 807.00 shares derived: sum of 2 quarters · filed 2026-03-25 | -6.90K shares derived: sum of 3 quarters · filed 2026-03-25 | 1.77K shares 10-K · filed 2026-03-25 | |
| 2024-09-30 | 807.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -6.90K shares derived: sum of 2 quarters · filed 2024-11-08 | 1.77K shares 10-Q · filed 2024-11-08 | -11.75K shares derived: sum of 4 quarters · filed 2025-03-25 | |
| 2024-06-30 | -7.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 966.00 shares 10-Q · filed 2024-08-09 | -12.56K shares derived: sum of 3 quarters · filed 2025-03-25 | -4.56K shares derived: sum of 4 quarters · filed 2025-03-25 | |
| 2024-03-31 | 8.67K shares 10-Q · filed 2024-05-10 | -4.85K shares derived: sum of 2 quarters · filed 2025-03-25 | 3.15K shares derived: sum of 3 quarters · filed 2025-03-25 | 12.57K shares derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-12-31 | -13.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -5.52K shares derived: sum of 2 quarters · filed 2025-03-25 | 3.90K shares derived: sum of 3 quarters · filed 2025-03-25 | 3.93K shares 10-K · filed 2025-03-25 | 35.28K shares 10-K · filed 2024-03-25 |
| 2023-09-30 | 8.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 17.42K shares derived: sum of 2 quarters · filed 2023-11-09 | 17.45K shares 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | 9.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 9.45K shares 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | 29.00 shares 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | 6.83K shares 10-K · filed 2024-03-25 | ||||
| 2022-06-30 | 30.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 115.83K shares 10-Q · filed 2022-08-12 | 90.12K shares derived: sum of 3 quarters · filed 2023-03-23 | 104.66K shares derived: sum of 4 quarters · filed 2023-03-23 | |
| 2022-03-31 | 85.61K shares 10-Q · filed 2022-07-08 | 59.90K shares derived: sum of 2 quarters · filed 2023-03-23 | 74.44K shares derived: sum of 3 quarters · filed 2023-03-23 | 86.44K shares derived: sum of 4 quarters · filed 2023-03-23 | |
| 2021-12-31 | -25.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -11.17K shares derived: sum of 2 quarters · filed 2023-03-23 | 828.00 shares derived: sum of 3 quarters · filed 2023-03-23 | 1.12K shares 10-K · filed 2023-03-23 | 44.29K shares 10-K · filed 2022-04-15 |
| 2021-09-30 | 14.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 26.54K shares derived: sum of 2 quarters · filed 2022-08-12 | 26.83K shares 10-Q · filed 2021-11-15 | 26.83K shares derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-06-30 | 12.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 12.30K shares 10-Q · filed 2022-08-12 | 12.30K shares derived: sum of 3 quarters · filed 2022-08-12 | 12.30K shares derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | 296.00 shares 10-Q · filed 2021-05-12 | 296.00 shares derived: sum of 2 quarters · filed 2022-07-07 | 296.00 shares derived: sum of 3 quarters · filed 2022-07-07 | 3.63K shares derived: sum of 4 quarters · filed 2022-07-07 | |
| 2020-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-07 | 0.00 shares derived: sum of 2 quarters · filed 2022-07-07 | 3.33K shares derived: sum of 3 quarters · filed 2022-07-07 | 3.33K shares 10-K/A · filed 2022-07-07 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 3.33K shares derived: sum of 2 quarters · filed 2021-11-15 | 3.33K shares 10-Q · filed 2021-11-15 | 6.67K shares derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | 3.33K shares 10-Q · filed 2021-08-12 | 3.33K shares 10-Q · filed 2020-08-06 | 6.67K shares derived: sum of 3 quarters · filed 2021-08-12 | ||
| 2020-03-31 | 3.33K shares 10-Q · filed 2021-05-12 | 3.33K shares derived: sum of 2 quarters · filed 2021-05-12 | |||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 4.87K shares 10-K · filed 2021-03-25 | |||
| 2019-09-30 | 4.87K shares 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | 4.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | 4.65K shares derived: sum of 2 quarters · filed 2020-03-04 | 6.15K shares 10-K · filed 2020-03-04 | ||
| 2018-09-30 | 67.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 1.57K shares 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 1.50K shares 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |